Glycemic control after total pancreatectomy for intraductal papillary mucinous neoplasm: An exploratory study

Laith H. Jamil, Ana M. Chindris, Kanwar R S Gill, Daniela Scimeca, John A. Stauffer, Michael G. Heckman, Shon E. Meek, Justin H Nguyen, Horacio J. Asbun, Massimo Raimondo, Timothy A. Woodward, Michael B. Wallace

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background. Glycemic control following total pancreatectomy (TP) has been thought to be difficult to manage. Diffuse intraductal papillary mucinous neoplasm (IPMN) is a potentially curable precursor to pancreatic adenocarcinoma, best treated by TP. Objective. Compare glycemic control in patients undergoing TP for IPMN to patients with type 1 diabetes mellitus (DM). Design/Setting. Retrospective cohort. Outcome Measure. Hemoglobin A1C(HbA1C) at 6, 12, 18, and 24 months after TP. In the control group, baseline was defined as 6 months prior to the first HbA1c measure. Results. Mean HgbA1C at each point of interest was similar between TP and type I DM patients (6 months (7.5 versus 7.7, P = 0.52), 12 months (7.3 versus 8.0, P = 0.081), 18 months (7.7 and 7.6, P = 0.64), and at 24 months (7.3 versus 7.8, P = 0.10)). Seven TP patients (50) experienced a hypoglycemic event compared to 65 type 1 DM patients (65, P = 0.38). Limitations. Small number of TP patients, retrospective design, lack of long-termfollowup. Conclusion. This suggests that glycemic control following TP for IPMNcan be well managed, similar to type 1 DM patients. Fear of DM following TP for IPMN should not preclude surgery when TP is indicated.

Original languageEnglish (US)
Article number381328
JournalHPB Surgery
Volume2012
DOIs
StatePublished - 2012

Fingerprint

Pancreatectomy
Neoplasms
Type 1 Diabetes Mellitus
Hypoglycemic Agents
Fear
Diabetes Mellitus
Hemoglobins
Adenocarcinoma
Outcome Assessment (Health Care)
Control Groups

ASJC Scopus subject areas

  • Hepatology
  • Surgery

Cite this

Jamil, L. H., Chindris, A. M., Gill, K. R. S., Scimeca, D., Stauffer, J. A., Heckman, M. G., ... Wallace, M. B. (2012). Glycemic control after total pancreatectomy for intraductal papillary mucinous neoplasm: An exploratory study. HPB Surgery, 2012, [381328]. https://doi.org/10.1155/2012/381328

Glycemic control after total pancreatectomy for intraductal papillary mucinous neoplasm : An exploratory study. / Jamil, Laith H.; Chindris, Ana M.; Gill, Kanwar R S; Scimeca, Daniela; Stauffer, John A.; Heckman, Michael G.; Meek, Shon E.; Nguyen, Justin H; Asbun, Horacio J.; Raimondo, Massimo; Woodward, Timothy A.; Wallace, Michael B.

In: HPB Surgery, Vol. 2012, 381328, 2012.

Research output: Contribution to journalArticle

Jamil, LH, Chindris, AM, Gill, KRS, Scimeca, D, Stauffer, JA, Heckman, MG, Meek, SE, Nguyen, JH, Asbun, HJ, Raimondo, M, Woodward, TA & Wallace, MB 2012, 'Glycemic control after total pancreatectomy for intraductal papillary mucinous neoplasm: An exploratory study', HPB Surgery, vol. 2012, 381328. https://doi.org/10.1155/2012/381328
Jamil, Laith H. ; Chindris, Ana M. ; Gill, Kanwar R S ; Scimeca, Daniela ; Stauffer, John A. ; Heckman, Michael G. ; Meek, Shon E. ; Nguyen, Justin H ; Asbun, Horacio J. ; Raimondo, Massimo ; Woodward, Timothy A. ; Wallace, Michael B. / Glycemic control after total pancreatectomy for intraductal papillary mucinous neoplasm : An exploratory study. In: HPB Surgery. 2012 ; Vol. 2012.
@article{a3043cf10bfa4e00ad92f8fd8a9f53ee,
title = "Glycemic control after total pancreatectomy for intraductal papillary mucinous neoplasm: An exploratory study",
abstract = "Background. Glycemic control following total pancreatectomy (TP) has been thought to be difficult to manage. Diffuse intraductal papillary mucinous neoplasm (IPMN) is a potentially curable precursor to pancreatic adenocarcinoma, best treated by TP. Objective. Compare glycemic control in patients undergoing TP for IPMN to patients with type 1 diabetes mellitus (DM). Design/Setting. Retrospective cohort. Outcome Measure. Hemoglobin A1C(HbA1C) at 6, 12, 18, and 24 months after TP. In the control group, baseline was defined as 6 months prior to the first HbA1c measure. Results. Mean HgbA1C at each point of interest was similar between TP and type I DM patients (6 months (7.5 versus 7.7, P = 0.52), 12 months (7.3 versus 8.0, P = 0.081), 18 months (7.7 and 7.6, P = 0.64), and at 24 months (7.3 versus 7.8, P = 0.10)). Seven TP patients (50) experienced a hypoglycemic event compared to 65 type 1 DM patients (65, P = 0.38). Limitations. Small number of TP patients, retrospective design, lack of long-termfollowup. Conclusion. This suggests that glycemic control following TP for IPMNcan be well managed, similar to type 1 DM patients. Fear of DM following TP for IPMN should not preclude surgery when TP is indicated.",
author = "Jamil, {Laith H.} and Chindris, {Ana M.} and Gill, {Kanwar R S} and Daniela Scimeca and Stauffer, {John A.} and Heckman, {Michael G.} and Meek, {Shon E.} and Nguyen, {Justin H} and Asbun, {Horacio J.} and Massimo Raimondo and Woodward, {Timothy A.} and Wallace, {Michael B.}",
year = "2012",
doi = "10.1155/2012/381328",
language = "English (US)",
volume = "2012",
journal = "HPB Surgery",
issn = "0894-8569",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Glycemic control after total pancreatectomy for intraductal papillary mucinous neoplasm

T2 - An exploratory study

AU - Jamil, Laith H.

AU - Chindris, Ana M.

AU - Gill, Kanwar R S

AU - Scimeca, Daniela

AU - Stauffer, John A.

AU - Heckman, Michael G.

AU - Meek, Shon E.

AU - Nguyen, Justin H

AU - Asbun, Horacio J.

AU - Raimondo, Massimo

AU - Woodward, Timothy A.

AU - Wallace, Michael B.

PY - 2012

Y1 - 2012

N2 - Background. Glycemic control following total pancreatectomy (TP) has been thought to be difficult to manage. Diffuse intraductal papillary mucinous neoplasm (IPMN) is a potentially curable precursor to pancreatic adenocarcinoma, best treated by TP. Objective. Compare glycemic control in patients undergoing TP for IPMN to patients with type 1 diabetes mellitus (DM). Design/Setting. Retrospective cohort. Outcome Measure. Hemoglobin A1C(HbA1C) at 6, 12, 18, and 24 months after TP. In the control group, baseline was defined as 6 months prior to the first HbA1c measure. Results. Mean HgbA1C at each point of interest was similar between TP and type I DM patients (6 months (7.5 versus 7.7, P = 0.52), 12 months (7.3 versus 8.0, P = 0.081), 18 months (7.7 and 7.6, P = 0.64), and at 24 months (7.3 versus 7.8, P = 0.10)). Seven TP patients (50) experienced a hypoglycemic event compared to 65 type 1 DM patients (65, P = 0.38). Limitations. Small number of TP patients, retrospective design, lack of long-termfollowup. Conclusion. This suggests that glycemic control following TP for IPMNcan be well managed, similar to type 1 DM patients. Fear of DM following TP for IPMN should not preclude surgery when TP is indicated.

AB - Background. Glycemic control following total pancreatectomy (TP) has been thought to be difficult to manage. Diffuse intraductal papillary mucinous neoplasm (IPMN) is a potentially curable precursor to pancreatic adenocarcinoma, best treated by TP. Objective. Compare glycemic control in patients undergoing TP for IPMN to patients with type 1 diabetes mellitus (DM). Design/Setting. Retrospective cohort. Outcome Measure. Hemoglobin A1C(HbA1C) at 6, 12, 18, and 24 months after TP. In the control group, baseline was defined as 6 months prior to the first HbA1c measure. Results. Mean HgbA1C at each point of interest was similar between TP and type I DM patients (6 months (7.5 versus 7.7, P = 0.52), 12 months (7.3 versus 8.0, P = 0.081), 18 months (7.7 and 7.6, P = 0.64), and at 24 months (7.3 versus 7.8, P = 0.10)). Seven TP patients (50) experienced a hypoglycemic event compared to 65 type 1 DM patients (65, P = 0.38). Limitations. Small number of TP patients, retrospective design, lack of long-termfollowup. Conclusion. This suggests that glycemic control following TP for IPMNcan be well managed, similar to type 1 DM patients. Fear of DM following TP for IPMN should not preclude surgery when TP is indicated.

UR - http://www.scopus.com/inward/record.url?scp=84866116801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866116801&partnerID=8YFLogxK

U2 - 10.1155/2012/381328

DO - 10.1155/2012/381328

M3 - Article

C2 - 22966212

AN - SCOPUS:84866116801

VL - 2012

JO - HPB Surgery

JF - HPB Surgery

SN - 0894-8569

M1 - 381328

ER -